Survodutide Phase 3 obesity data detailed

Boehringer Ingelheim is evaluating its obesity drug candidate survodutide in a Phase 3 obesity study, according to reporting from Endpoints News on June 7, 2026. The trial is part of a late-stage development program aimed at assessing the therapy’s effects in people living with obesity.

Survodutide is a licensed asset from Zealand Pharma. The collaboration places Boehringer Ingelheim in charge of the clinical program, while Zealand Pharma retains its role as the originator of the molecule. The ongoing Phase 3 trial represents a key step in advancing the candidate toward potential registration.

Endpoints News reported that survodutide’s weight-loss efficacy in the Phase 3 obesity study appeared to be on par with Wegovy. This comparison, made in the context of the Phase 3 readout, indicates that the magnitude of weight reduction observed with survodutide aligned with that of an established obesity therapy.

Headlines cited by Business Insider highlighted additional metabolic findings from the Phase 3 program. The reported coverage stated that the Phase 3 trial in people living with obesity showed a targeted 34% reduction in visceral fat and a 63% reduction in liver fat in a pre-specified analysis, while minimizing loss of lean mass. These outcomes were described as supporting improved metabolic effects in the treated population.

Taken together, the weight-loss performance reported by Endpoints News and the fat-distribution and liver-related findings cited in the Business Insider headlines position survodutide as a late-stage obesity candidate with multiple efficacy readouts, including body weight, visceral fat, and liver fat.

Despite the efficacy signals, tolerability challenges were also reported in the Phase 3 trial. Endpoints News noted a 19% rate of treatment discontinuation for survodutide, driven by gastrointestinal adverse events. These events were highlighted as a key factor behind patients stopping treatment in the study.

The gastrointestinal-related discontinuations were discussed in the context of late-stage obesity drug development, where balancing efficacy with tolerability is a central consideration. The reported 19% discontinuation rate underscores that gastrointestinal side effects were a notable feature of survodutide’s Phase 3 safety and tolerability profile.

The Endpoints News article formed part of coverage linked to ADA26, focusing on emerging obesity therapeutics and late-stage clinical readouts. Within this broader context, survodutide’s data were presented as one of the key Phase 3 updates in the obesity field.

By emphasizing both the weight-loss results and the discontinuation rate due to gastrointestinal adverse events, the coverage framed survodutide as a candidate showing efficacy on par with an established product, while also facing tolerability issues characteristic of this drug class. The additional Phase 3 findings cited in Business Insider headlines on visceral and liver fat reduction add further detail to the emerging clinical profile of the drug.